Abstract | BACKGROUND: METHODS AND RESULTS: Patients who had an out-of-hospital cardiac arrest with ventricular fibrillation that persisted after 3 shocks from an external defibrillator, intravenous epinephrine, and another shock were retrospectively studied. The patients received lidocaine from January 1997 through June 2001 and nifekalant from July 2001 through December 2004. Short-term survival rates (survival to hospital admission and 24-h survival) were compared between the groups. The study group comprised 120 patients (mean age: 62+/-16 years): 55 received nifekalant and 65 received lidocaine. Age, sex, history of ischemic heart disease, whether arrest was witnessed or not and time to arrival at the hospital did not differ significantly between the groups. As compared with lidocaine, nifekalant was associated with significantly higher rates of survival to hospital admission (67% vs 37%, p<0.001) and 24-h survival (53% vs 31%, p=0.01). Multivariate analysis showed that treatment with nifekalant and early initiation of cardiopulmonary resuscitation were independent predictors of 24-h survival. CONCLUSIONS:
|
Authors | Yoshio Tahara, Kazuo Kimura, Masami Kosuge, Toshiaki Ebina, Shinichi Sumita, Kiyoshi Hibi, Hideshi Toyama, Takayuki Kosuge, Yoshihiro Moriwaki, Noriyuki Suzuki, Mitsugi Sugiyama, Satoshi Umemura |
Journal | Circulation journal : official journal of the Japanese Circulation Society
(Circ J)
Vol. 70
Issue 4
Pg. 442-6
(Apr 2006)
ISSN: 1346-9843 [Print] Japan |
PMID | 16565562
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Anti-Arrhythmia Agents
- Pyrimidinones
- nifekalant
- Lidocaine
- Epinephrine
|
Topics |
- Aged
- Anti-Arrhythmia Agents
(therapeutic use)
- Cardiopulmonary Resuscitation
- Epinephrine
(therapeutic use)
- Female
- Heart Arrest
(drug therapy, mortality, physiopathology)
- Humans
- Lidocaine
(therapeutic use)
- Male
- Middle Aged
- Multivariate Analysis
- Pyrimidinones
(therapeutic use)
- Retrospective Studies
- Survival Rate
- Time Factors
- Ventricular Fibrillation
(drug therapy, etiology, mortality)
|